Clinical trial
A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function
NCT02862600 is registered in ClinicalTrials.gov with Heart Metabolics Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function
- Lead sponsor
- Heart Metabolics Limited
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 1, 2016
- Completion date
- May 22, 2017
- Enrollment
- 35 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.